Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma

We conducted a phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) and KPd with daratumumab (Dara-KPd) in relapsed/refractory multiple myeloma. The primary end points were identification of a maximum tolerated dose (MTD) of KPd for phase 1, and rates of overall response (ORR) and n...

Descripción completa

Detalles Bibliográficos
Autores principales: Derman, Benjamin A., Zonder, Jeffrey, Reece, Donna, Cole, Craig, Berdeja, Jesus, Stefka, Andrew T., Major, Ajay, Kin, Andrew, Griffith, Kent, Jasielec, Jagoda, Jakubowiak, Andrzej J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539870/
https://www.ncbi.nlm.nih.gov/pubmed/36763537
http://dx.doi.org/10.1182/bloodadvances.2022008866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539870/
https://www.ncbi.nlm.nih.gov/pubmed/36763537
http://dx.doi.org/10.1182/bloodadvances.2022008866

Ejemplares similares